Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Botulinum Toxin Type A

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    228 result(s) found for: Botulinum Toxin Type A. Displaying page 8 of 12.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    EudraCT Number: 2006-002143-83 Sponsor Protocol Number: 191622-515 Start Date*: 2006-07-25
    Sponsor Name:Allergan Ltd
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment with Two Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified N...
    Medical condition: Urinary Incontinence Due to Neurogenic Detrusor Overactivity
    Disease: Version SOC Term Classification Code Term Level
    9.0 10029279 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) AT (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-005124-18 Sponsor Protocol Number: LUMC-NEUR-0001 Start Date*: 2012-07-12
    Sponsor Name:Leiden University Medical Center
    Full Title: Chronification and reversibility of migraine
    Medical condition: Patients suffering from chronic migraine and medication overuse
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10066636 Chronic migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001936-59 Sponsor Protocol Number: 191622-077 Start Date*: 2005-07-30
    Sponsor Name:ALLERGAN LTD
    Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel-group, dose-response study of the safety and efficacy of a single treatment of BOTOX® (botulinum toxin type A) purified neuroto...
    Medical condition: Idiopathic overactive bladder (symptoms of frequency and urgency) with urinary incontinence.
    Disease: Version SOC Term Classification Code Term Level
    7.1 10059617 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021817-22 Sponsor Protocol Number: Y-52-52120-153 Start Date*: 2014-01-29
    Sponsor Name:IPSEN INNOVATION
    Full Title: A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, CONTROLLED, MULTIPLE TREATMENT STUDY ASSESSING EFFICACY AND SAFETY OF DYSPORT USED IN THE TREATMENT OF UPPER LIMB SPASTICITY IN CHIL...
    Medical condition: Upper limb spasticity in children
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004852 10048970 Arm spasticity LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) PL (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-009357-22 Sponsor Protocol Number: 08/0257 Start Date*: 2009-03-09
    Sponsor Name:University College London
    Full Title: A phase IV randomised, placebo controlled, double-blind, single centre, out-patient trial to investigate the functional benefit of botulinum toxin injections combined with physiotherapy treatment f...
    Medical condition: upper limb spasticity after stroke
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014498 Embolic stroke LLT
    9.1 10019016 Haemorrhagic stroke LLT
    9.1 10023027 Ischaemic stroke NOS LLT
    9.1 10027580 Middle cerebral artery stroke LLT
    9.1 10042244 Stroke LLT
    9.1 10043647 Thrombotic stroke LLT
    9.1 10048863 Hemorrhagic stroke LLT
    9.1 10055221 Ischemic stroke LLT
    9.1 10057613 Thromboembolic stroke LLT
    9.1 10061256 Ischaemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2012-005496-14 Sponsor Protocol Number: MRZ60201_3072_1 Start Date*: Information not available in EudraCT
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, multicenter, randomized, double-blind, parallel-group, dose-response study of three doses Xeomin® (incobotulinumtoxinA, NT 201) for the treatment of upper limb spasticity alone or comb...
    Medical condition: Upper limb spasticity or combined upper and lower limb spasticity in children and adolescents (age 2 - 17 years) with cerebral palsy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10058977 Spastic paresis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005054-30 Sponsor Protocol Number: MRZ60201_3070_1 Start Date*: 2013-04-08
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, multicenter, randomized, double-blind, parallel-group, dose-response study of three doses Xeomin® (incobotulinumtoxinA, NT 201) for the treatment of lower limb spasticity in children a...
    Medical condition: Lower limb spasticity due to cerebral palsy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10058977 Spastic paresis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) AT (Completed) DE (Completed) SK (Completed) CZ (Completed) ES (Completed) Outside EU/EEA FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-002461-35 Sponsor Protocol Number: PREBOTPilot Start Date*: 2019-12-06
    Sponsor Name:Ruprecht-Karls-University Heidelberg Medical Faculty represented by Universitätsklinikum Heidelberg and its acting Comm
    Full Title: Monocenter, randomized, controlled, open-label, phase-II clinical trial of PREoperative endoscopic injection of BOTulinum toxin in the sphincter of Oddi to reduce postoperative pancreatic fistula a...
    Medical condition: Elective distal pancreatectomy for any underlying disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10013476 Distal pancreatectomy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012073-34 Sponsor Protocol Number: R0000063 Start Date*: 2009-07-08
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Botulinum toxin for treating calf muscle spasticity in Hereditary Spastic Paraparesis (HSP): functional effects on dynamic balance and gait
    Medical condition: Subjects with hereditary spastic paraparesis (HSP)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019903 Hereditary spastic paraplegia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004281-17 Sponsor Protocol Number: 191622-517 Start Date*: 2007-12-18
    Sponsor Name:Allergan Inc.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Com...
    Medical condition: Patients with lower urinary tract symptoms due to Benign Prostatic Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) IT (Completed) GB (Completed) CZ (Completed) AT (Completed) DE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-019997-33 Sponsor Protocol Number: 2010/03 Start Date*: 2010-06-02
    Sponsor Name:Leiden University Medical Center
    Full Title: Responsiveness to botulinum toxinum type A in complex regional pain syndrome related fixed dystonia
    Medical condition: CRPS with dystonia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10013983 Dystonia LLT
    12.1 10038249 Reflex sympathetic dystrophy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004980-63 Sponsor Protocol Number: 191622-116 Start Date*: 2012-02-08
    Sponsor Name:Allergan Ltd.
    Full Title: BOTOX® Treatment in Adult Patients with Post-Stroke Lower Limb Spasticity
    Medical condition: Post-Stroke Lower Limb Spasticity
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004852 10042244 Stroke LLT
    16.1 100000004852 10024132 Leg spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GB (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003948-71 Sponsor Protocol Number: D-FR-59011-002 Start Date*: 2020-07-29
    Sponsor Name:Ipsen Innovation
    Full Title: AN INTEGRATED PHASE I/II, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, DYSPORT AND PLACEBO-CONTROLLED, DOSE ESCALATION AND DOSE-FINDING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPN59011 IN THE TREATM...
    Medical condition: Upper limb spasticity after stroke or traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) BG (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013089-26 Sponsor Protocol Number: 191622-096 Start Date*: 2009-09-16
    Sponsor Name:Allergan Ltd
    Full Title: A Multicenter, Long-term Follow-up Study of the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Idiopathic Overactive Bladder with Urinary Incont...
    Medical condition: Patients with symptoms of idiopathic overactive bladder (frequency and urgency)with urinary incontinence, whose symptoms have not been adequately managed with anticholinergic therapy.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020172-30 Sponsor Protocol Number: 191622-100 Start Date*: 2010-08-16
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Intraprostatic Administration of BOTOX® 200 U (Botulinum Toxin Type A) Purified Neur...
    Medical condition: Treatment of Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) BE (Completed) FR (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001068-36 Sponsor Protocol Number: R03465 Start Date*: 2014-10-22
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Onabotulinum toxin-A versus extended release tolterodine in the management of idiopathic overactive bladder in children: A pilot randomised controlled trial (OVERT)
    Medical condition: Idiopathic Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001779-38 Sponsor Protocol Number: MRZ60201_2069_1 Start Date*: 2011-11-30
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, randomized, double-blind, placebo-controlled, parallel-group, 3-stage dose-finding study to identify a safe and effective dose of NT 201 for unilateral injection into the soft palate f...
    Medical condition: Habitual snoring
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10041235 Snoring PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003983-30 Sponsor Protocol Number: CPH-303-201400 Start Date*: 2019-05-22
    Sponsor Name:Croma-Pharma GmbH
    Full Title: Randomized double blind Phase 3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study.
    Medical condition: Moderate to severe glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000600-42 Sponsor Protocol Number: I5Q-MC-CGAW Start Date*: 2018-06-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults with Treatment-Resistant Migraine - The CONQUER Study
    Medical condition: Treatment-resistant Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027602 Migraine headache LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) CZ (Completed) BE (Completed) NL (Completed) HU (Completed) DK (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000735-26 Sponsor Protocol Number: AGN/HO/SPA/001-191622 Start Date*: 2007-06-18
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicentre, Double-Blind, Prospective, Randomised, European and Canadian Study to Evaluate Patient Outcomes and Costs of Managing Adults with Spasticity and Associated Focal Spasticity.
    Medical condition: Spasticity and Associated Focal Spasticity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 21:49:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA